Set Your Location to See Relevant Information

Setting your location helps us to show you nearby providers and locations based on your healthcare needs.

Stamford Health is committed to stopping the spread of infectious diseases such as COVID-19. For information regarding important service updates, FAQs and more, click HERE. To speak with a member of our care team, call 203.276.4111

DAPHNe: De-escalation to adjuvant antibodies post-pCR to Neoadjuvant THP (paclitaxel/trastuzumab/pertuzumab) - a pilot study in HER-2 positive breast cancer (DF/HCC 18-394)

Study Details

This research study is studying whether participants and their doctors are willing to determine post-surgery treatment on the basis of response to pre-surgery treatment, and studying blood and tissue collected from participants treated with a combination of drugs as a treatment for breast cancer.

The names study drugs involved in this study are:

  • Paclitaxel (also called Taxol)
  • Trastuzumab (also called Herceptin)
  • Pertuzumab (also called Perjeta)

Learn More NCT number

Principal Investigators

  • Steve Lo, MD
Mary Miller, LPN at 203-358-8879


  • Bennett Cancer Center
    One Hospital Plaza
    Stamford, CT 06902
    Main: 203-276-2695

Our website uses cookies

This website uses cookies to give you the very best experience. Your continued use of this site is considered permission by you to use cookies in this manner. Please review our Privacy Policy and Terms of Use for more information about the data we collect and the types of cookies we use. Please note, if you link off our website to a 3rd party site of any kind, that website has its own terms and conditions.